In 2023, Renin-Angiotensin System Medicine sales in Spain stood at 970.5 million USD. Forecasts for the upcoming years show a steady decline, with sales values projected to be 956.8 million USD in 2024, 943.3 million USD in 2025, 930.1 million USD in 2026, 917.2 million USD in 2027, and 904.7 million USD in 2028. The year-on-year variation shows a decrease of approximately 1.3% from 2023 to 2024, 1.4% from 2024 to 2025, 1.4% from 2025 to 2026, 1.4% from 2026 to 2027, and another 1.4% from 2027 to 2028. The compound annual growth rate (CAGR) from 2024 to 2028 is -1.5%. This steady decline suggests a sustained decrease in sales over the forecast period.
Future trends to watch for include potential shifts in healthcare policies, advancements in alternative therapies, and economic factors that could influence both pricing and demand for Renin-Angiotensin System medicines. Monitoring these trends will be crucial for understanding and anticipating further changes in the market.
